Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal

Michael B. Boffa, Saverio Stranges, Neil Klar, Patrick M. Moriarty, Gerald F. Watts, Marlys L. Koschinsky

Research output: Contribution to journalReview articlepeer-review

24 Citations (Scopus)


Elevated plasma concentrations of lipoprotein(a) [Lp(a)] are an independent, and possibly causal, risk factor for atherothrombotic diseases including coronary heart disease. The principal evidence base for this comes from large population studies focusing on first atherothrombotic events. However, inconsistent findings have been reported from studies investigating the impact of elevated Lp(a) on atherothrombotic events in subjects with preexisting cardiovascular disease. This question is very important because the secondary prevention population is recommended for Lp(a) screening by some guidelines and could be an important target group for Lp(a)-lowering therapies that are currently on the horizon. In this review, we survey the secondary prevention literature as it relates to Lp(a) and identify some possible confounding factors that may underlie the inconsistent findings, such as index event bias.

Original languageEnglish
Pages (from-to)1358-1366
Number of pages9
JournalJournal of Clinical Lipidology
Issue number6
Publication statusPublished - 1 Nov 2018


Dive into the research topics of 'Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal'. Together they form a unique fingerprint.

Cite this